The complex, tri­chlorido­(1,4,11-tri­aza-8-azonia­tetra­cyclo­[6.6.2.04,16.011,15]hexa­decane 1-oxide-κO)zinc(II) monohydrate, [ZnCl3(C12H23N4O)]·H2O, (I), has monoclinic symmetry (space group P21/n) at 120 K. The zinc(II) center adopts a slightly distorted tetra­hedral coordination geometry and is coordinated by three chlorine atoms and the oxygen atom of the oxidized tertiary amine of the tetra­cycle. The amine nitro­gen atom, inside the ligand cleft, is protonated and forms a hydrogen bond to the oxygen of the amine oxide. Additional hydrogen-bonding inter­actions involve the protonated amine, the water solvate oxygen atom, and one of the chloro ligands.

The unique valve design of V-traps makes them virtually trouble free. They are self-priming; you never have to add water to make them work. A self-sealing column of water, equal in height to the negative pressure in the air conditioner, automatically prevents air from entering the drain trap allowing the condensate to drain freely.

_{-- Delivered by Feed43 service}

Type I and III interferons induce expression of the “myxovirus resistance proteins” MxA in human cells and its ortholog Mx1 in murine cells. Human MxA forms cytoplasmic structures, whereas murine Mx1 forms nuclear bodies. Whereas both HuMxA and MuMx1 are antiviral toward influenza A virus (FLUAV) (an orthomyxovirus), only HuMxA is considered antiviral toward vesicular stomatitis virus (VSV) (a rhabdovirus). We previously reported that the cytoplasmic human GFP-MxA structures were phase-separated membraneless organelles (“biomolecular condensates”). In the present study, we investigated whether nuclear murine Mx1 structures might also represent phase-separated biomolecular condensates. The transient expression of murine GFP-Mx1 in human Huh7 hepatoma, human Mich-2H6 melanoma, and murine NIH 3T3 cells led to the appearance of Mx1 nuclear bodies. These GFP-MuMx1 nuclear bodies were rapidly disassembled by exposing cells to 1,6-hexanediol (5%, w/v), or to hypotonic buffer (40–50 mosm), consistent with properties of membraneless phase-separated condensates. Fluorescence recovery after photobleaching (FRAP) assays revealed that the GFP-MuMx1 nuclear bodies upon photobleaching showed a slow partial recovery (mobile fraction: ∼18%) suggestive of a gel-like consistency. Surprisingly, expression of GFP-MuMx1 in Huh7 cells also led to the appearance of GFP-MuMx1 in 20–30% of transfected cells in a novel cytoplasmic giantin-based intermediate filament meshwork and in cytoplasmic bodies. Remarkably, Huh7 cells with cytoplasmic murine GFP-MuMx1 filaments, but not those with only nuclear bodies, showed antiviral activity toward VSV. Thus, GFP-MuMx1 nuclear bodies comprised phase-separated condensates. Unexpectedly, GFP-MuMx1 in Huh7 cells also associated with cytoplasmic giantin-based intermediate filaments, and such cells showed antiviral activity toward VSV.

Self-assembled silica condensates are described as well as their use in coating compositions. The self-assembled silica condensates can be formed from the hydrolysis of medium to long chain trialkoxy silane compounds. Coating compositions containing the self-assembled silica condensates can provide coatings having improved scratch and mar resistance and can have excellent recoat adhesion.

Process for the preparation of etherified melamine/formaldehyde condensates, in which first a methylolation of melamine with a formaldehyde component in the molar ratio of from 1:6 to 1:15, preferably at a pH of >7, is carried out. This is followed by an etherification of the resulting hydroxymethylation intermediate in the presence of a C1-C20-alkyl, preferably of a C1-C6-alcohol, particularly preferably of a C1-C4-alcohol, at a pH of 9.5 being established before, during and/or after the distillation. According to the invention, a plurality of hydroxymethylation, etherification and distillation steps follow in order to achieve an etherified melamine/formaldehyde condensate which is distinguished by a high degree of hydroxymethylation, a high solids content and a low viscosity.

A condensing fuel-fired appliance has a condensate trap that includes a trap body; a float; a flue gas inlet port for the introduction of flue gas into the interior region of the trap body; a condensate outlet port for the discharge of condensate from the interior region; and a flue gas outlet port for the discharge of flue gas from the interior region of the trap body. The float is configured to move in response to condensate collected in the interior region of the trap body to a position to substantially block the discharge of flue gas from the interior region through the flue gas outlet port. The float is also configured to move to a position to substantially block the discharge of flue gas from the interior region through the condensate outlet port when there is little or no condensate in the interior region of the trap body.

A condensate collector system includes a condensate collector box having at least one condensate outlet port, and a condensate trap fluidly connected to the at least one condensate outlet port. The condensate trap is configured and disposed to be selectively positioned in multiple drain orientations relative to the condensate collector box to accommodate multiple installation configurations of the multi-poise gas furnace.